People · Operator
Named in public records as an officer, director or promoter · active 2009–2022 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Fog Pharmaceuticals, Inc. | — | Pharmaceuticals | Series D+ | $278.4M | $3.1B | 2022 |
| Synlogic, Inc. | — | Biotechnology | Series C | $186.5M | $3.3B | 2011 |
| iPierian, Inc. | — | Pharmaceuticals | Series B | $87.3M | $985.1M | 2010 |
| Limerick Biopharma Inc | — | Pharmaceuticals | Series B | $52.8M | $16.3M | 2009 |
Corey S. Goodman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Corey S. Goodman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Corey Goodman | 3 | 13 |
| Peter Barrett | 1 | 18 |
| John Walker | 1 | 17 |
| Kristina Burow | 1 | 16 |
| Beth Seidenberg | 1 | 15 |
| Michael Powell | 1 | 14 |
| Edward Mathers | 1 | 12 |
| Ed Mathers | 1 | 11 |
| Chad Waite | 1 | 11 |
| Chau Khuong | 1 | 9 |
| Steve Dow | 1 | 7 |
| Scott Minick | 1 | 7 |
| Daniel Geffken | 1 | 6 |
| Elaine Jones | 1 | 6 |
| Lewis Geffen | 1 | 6 |
| Paul Miller | 1 | 5 |
| Evan S. Melrose | 1 | 5 |
| Nick Leschly | 1 | 5 |
| Stephen Dow | 1 | 4 |
| Beth F. Seidenberg | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.